Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:VCYT

Veracyte Q3 2026 Earnings Date & Estimates

Veracyte logo
$46.22 +1.43 (+3.19%)
Closing price 10/21/2026 04:00 PM Eastern
Extended Trading
$46.72 +0.50 (+1.08%)
As of 10/21/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Veracyte is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for November 5, 2026 at 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Veracyte in Q3 2026

Veracyte is expected to post earnings of $0.4111 per share on revenue of $147.16 million. In the same quarter a year earlier Veracyte reported $0.51 per share on revenue of $131.87 million. Veracyte last reported on July 30, 2026, posting $0.54 per share and beating the $0.4103 consensus estimate. Veracyte has beaten the consensus EPS estimate in 8 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.4111
Expected Revenue
$147.16 million
Prior-Year EPS
$0.51
Prior-Year Revenue
$131.87 million
Expected EPS Growth
-19.4%
Expected Revenue Growth
+11.6%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.54 (Beat by +$0.1297)
Last Quarter Revenue
$150.32 million
EPS Beat Rate
8 of last 8 quarters

Prepare for the Q3 2026 Call

Veracyte Q3 2026 Earnings FAQ

Veracyte (NASDAQ:VCYT) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Veracyte's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Veracyte to post earnings of $0.4111 per share for Q3 2026.

The consensus revenue estimate for Veracyte is $147.16 million for Q3 2026.

Veracyte Earnings Headlines

Veracyte (NASDAQ:VCYT) Shares Break Below Two Hundred Day Moving Average - Here's What Happened
October 20 at 4:12 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31138619
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
October 19 at 12:42 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/six-studies-to-highlight-veracyte-s-genomic-tests-across-breast-prostate-and-bladder-cancer-at-esmo-2026-1036638705
You haven't downloaded this yet
Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.tc pixel
 |  Profits Run (Ad)
Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
October 19 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/19/3383396/0/en/six-studies-to-highlight-veracyte-s-genomic-tests-across-breast-prostate-and-bladder-cancer-at-esmo-2026.html
Veracyte's Prosigna Breast Cancer Recurrence Test Gets Medicare Coverage
October 16, 2026  |  marketscreener.comM
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
October 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/16/3382619/0/en/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test.html
See More Veracyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Veracyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veracyte and other key companies, straight to your email.

About Veracyte

Veracyte (NASDAQ:VCYT) is a diagnostics company that develops genomic tests to help physicians diagnose cancer, assess disease risk and guide treatment decisions. Its tests are designed to provide additional molecular information from patient samples, often helping reduce uncertainty and support more personalized care.

The company’s portfolio includes Afirma tests for thyroid nodules, Decipher tests for prostate cancer, Percepta tests for lung cancer and Envisio tests for breast cancer. Veracyte also develops and commercializes additional genomic assays intended for use across various cancer types and clinical settings.

Founded in 2008 and headquartered in South San Francisco, California, Veracyte primarily serves the U.S. health care market through relationships with physicians, health systems, laboratories and biopharmaceutical companies. Its products are also available in select international markets. The company is led by President and Chief Executive Officer Marc Stapley.

View Veracyte Profile
Earnings Tools